BioArctic receives patent in Japan for new antibodies targeting Parkinson's disease
The granted substance patent (based on Japanese patent application no. 2021-570377) focuses on the monoclonal antibody BAN0805, which selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while sparing the physiological monomer form of alpha-synuclein. The aim is to develop a treatment that halts or slows the progression of Parkinson's disease.
At the International Congress of Parkinson's disease and movement disorders® (MDS) in September 2021, results presented from the Phase 1 study with BAN0805 supported continued development of the antibody in Phase 2 with once-monthly dosing.
"I am delighted to announce that the Japanese Patent Office is granting a new drug substance patent for BAN0805, securing a valuable and extensive period of patent protection," says Gunilla Osswald, CEO of BioArctic. "This patent further strengthens BioArctic's patent portfolio and supports our important efforts to develop potential treatments in Parkinson's disease and other synucleinopathies."
The information was released for public disclosure, through the agency of the contact person below, on August 23, 2023, at 10.45 a.m. CET.
For further information, please contact:
Oskar Bosson, Vice President Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
Jiang Millington, Corporate Communication and Social Media Director
E-mail: jiang.millington@bioarctic.se
Phone: +46 79 33 99 166
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University,
The following files are available for download:
BioArctic receives patent in |
View original content:https://www.prnewswire.com/news-releases/bioarctic-receives-patent-in-japan-for-new-antibodies-targeting-parkinsons-disease-301907860.html
SOURCE BioArctic
